Julie Broe Honore is currently the Head of Clinical Development, Medical, and Regulatory Affairs at Novo Nordisk Korea. After gaining clinical experience in various medical fields—including internal medicine, psychiatry, cardiology, and oncology—she joined Novo Nordisk in 2015, where she has since led clinical trials for major disease areas such as diabetes, cardiovascular disease, and Alzheimer’s disease, contributing to global drug development efforts.

A graduate of Copenhagen Business School, she now oversees clinical strategy, regulatory affairs, and health policy engagement for Novo Nordisk in Korea. With her multidisciplinary clinical expertise and global experience in new drug development, Julie Broe Honore plays a leading role in ensuring the safe and effective introduction of innovative therapies to the Korean market.